Synaptic Vesicle Protein 2 (SV2) Isoforms |
Bandala, Cindy
(Research Support Group, National Institute of Rehabilitation, Escuela Superior de Medicina, Instituto Politecnico Nacional)
Miliar-Garcia, A. (Oncology and Oxidative Stress Laboratory, Escuela Superior de Medicina, Instituto Politecnico Nacional) Mejia-Barradas, C.M. (Research Support Group, National Institute of Rehabilitation, Escuela Superior de Medicina, Instituto Politecnico Nacional) Anaya-Ruiz, M. (Molecular Biology Laboratory, Escuela Superior de Medicina, Instituto Politecnico Nacional) Luna-Arias, J.P. (Cell Biology Laboratory, Eastern Biomedical Research Center, Instituto Mexicano del Seguro Social) Bazan-Mendez, C.I. (Cell Biology Laboratory, Eastern Biomedical Research Center, Instituto Mexicano del Seguro Social) Gomez-Lopez, M. (Oncology and Oxidative Stress Laboratory, Escuela Superior de Medicina, Instituto Politecnico Nacional) Juarez-Mendez, S. (Cell Biology Laboratory, CINVESTAV) Lara-Padilla, E. (Research Support Group, National Institute of Rehabilitation, Escuela Superior de Medicina, Instituto Politecnico Nacional) |
1 | Shi J, Anderson D, Lynch BA, et al (2011). Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding. Biochem Soc Trans, 39, 1341-47 DOI |
2 | Simpson LL (1979). Studies on the mechanism of action of botulinum toxin. Adv Cytopharmacol, 3, 27-34 |
3 | Zhang Q, Fan H, Shen J, Hoffman RM, Xing HR (2010). Human breast cancer cell lines co-express neuronal, epithelial, and melanocytic differentiation markers in vitro and in vivo. PLoS One, 5,9712 DOI |
4 | Zhenzhen Z, De'an T, Limin X, Wei Y, Min L (2012). New Candidate Tumor-Suppressor Gene KLF6 and its Splice Variant KLF6 SV2 Counterbalancing Expression in Primary Hepatocarcinoma. Hepatogastroenterology, 59, 473-76 |
5 | Ahnert-Hilger G, Kutay U, Chahoud I, Rapoport T, Wiedenmann B (1996) Synaptobrevin is essential for secretion but not for the development of synaptic processes. Eur J Cell Biol 70, 1-11 DOI |
6 | Arnon SS, Schechter R, Inglesby TV, et al (2001). Botulinum toxin as a biological weapon: medical and public health management. JAMA, 285, 1059-70 DOI ScienceOn |
7 | Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH (1994). Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci, 14, 5223-35 |
8 | Bajjalieh SM, Peterson K, Linial M, Scheller RH (1993). Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci U S A, 90, 2150-54 DOI |
9 | Blum FC, Chen C, Kroken AR, Barbieri JT (2012). Tetanus toxin and botulinum toxin a utilize unique mechanisms to enter neurons of the central nervous system. Infect Immun 80, 1662-69 DOI |
10 | Bumming P, Nilsson O, Ahlman H, et al (2007). Gastrointestinal stromal tumors regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype. Endocr Relat Cancer 14, 853-63 DOI |
11 | Coelho A, Dinis P, Pinto R, et al (2010). Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 57, 884-90 DOI |
12 | de Groot M, Aronica E, Heimans JJ, Reijneveld JC (2011). Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology, 77, 532-39 DOI |
13 | Chan DA, Giaccia AJ (2007). Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev, 26, 333-39 DOI |
14 | Chancellor MB, Fowler CJ, Apostolidis A, et al (2008). Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol, 5, 319-28 |
15 | Choi J, Hwang YK, Choi YJ, et al (2007). Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. J Korean Med Sci, 22, 17-23 DOI |
16 | de Groot M, Toering ST, Boer K, et al (2010). Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex. Neuro Oncol, 12: 265-73 DOI |
17 | Dong M, Yeh F, Tepp WH, et al (2006). SV2 is the protein receptor for botulinum neurotoxin A. Science, 312, 592-96 DOI |
18 | Gillies RJ, Gatenby RA (2007) Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev, 26, 311-17 DOI |
19 | Gronberg M, Amini RM, Stridsberg M, Janson ET, Saras J (2010). Neuroendocrine markers are expressed in human mammary glands. Regul Pept, 160, 68-74 DOI |
20 | Hanoun N, Bureau C, Diab T, et al (2010). The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions. J Hepatol 53, 880-88 DOI |
21 | Jakobsen AM, Ahlman H, Wangberg B, et al (2002). Expression of synaptic vesicle protein 2 (SV2) in neuroendocrine tumours of the gastrointestinal tract and pancreas. J Pathol, 196, 44-50 DOI |
22 | Li Q, Johansson H, Grimelius L (1999). Innervation of human adrenal gland and adrenal cortical lesions. Virchows Arch, 435, 580-89 DOI |
23 | Janz R, Hofmann K, Sudhof TC (1998). SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel transport functions of synaptic vesicles. J Neurosci, 18, 9269-81 |
24 | Janz R, Sudhof TC (1999). SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience, 94, 1279-90 DOI |
25 | Karsenty G, Rocha J, Chevalier S, et al (2009). Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. Prostate, 69, 1143-50 DOI |
26 | Lukashev D, Ohta A, Sitkovsky M (2007). Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev, 26, 273-79 DOI |
27 | McPherson K, Steel CM, Dixon JM (2000). ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321, 624-28 DOI |
28 | Montal M (2010). Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem, 79, 591-617 DOI |
29 | Nilsson O, Jakobsen AM, Kolby L, Bernhardt P, Forssell- Aronsson E, Ahlman H (2004). Importance of vesicle proteins in the diagnosis and treatment of neuroendocrine tumors. Ann N Y Acad Sci, 1014, 280-83 DOI |
30 | Portela-Gomes GM, Lukinius A, Grimelius L (2000). Synaptic vesicle protein 2, A new neuroendocrine cell marker. Am J Pathol, 157, 1299-1309 DOI |
31 | Schiavo G, Matteoli M, Montecucco C (2000). Neurotoxins affecting neuroexocytosis. Physiol Rev, 80, 717-66 |